CStone announces first patient dosed in the global proof-of-concept study of CS1001 in combination with Bayer's regorafenib |
| January 24, 2020 | January 2020 Bond Updates |
|
SUZHOU, China, Jan. 24, 2020 /PRNewswire/ --CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) recently announced that it has dosed the first patient in Australia in a clinical trial of CS1001, an investigational PD-L1 inhibitor developed by CStone, in combination with... |
| View more at: https://www.prnewswire.com:443/news-releases/cstone-announces-first-patient-dosed-in-the-global-proof-of-concept-study-of-cs1001-in-combination-with-bayers-regorafenib-300992673.html |
| Related News |
|